ArticleThe Canadian journal of hospital pharmacy2026
Management of Status Epilepticus in Children before and after Implementation of a Treatment Algorithm.
Article in The Canadian journal of hospital pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pharmacological management of status epilepticus (SE) in children must be rapid and optimal to limit morbidity and mortality. Objectives: The primary objective was to compare SE management in children before and after the implementation of a drug treatment algorithm. The secondary objective was to describe the compliance of SE management with the algorithm following its implementation. Methods: This evaluative cross-sectional population study with retrospective chart review was performed in a 5-site teaching hospital, which included a tertiary pediatric hospital. Eligible patients were between 1 month and under 18 years of age, had a diagnosis of SE, and received antiseizure medication (ASM) between January 1, 2019, and April 1, 2023. Results: The study involved 108 patients, 60 treated before algorithm implementation and 48 treated after implementation. In both groups, most patients received a benzodiazepine (BZD) as first-line treatment (96% [52/54] and 100% [44/44], respectively). For second-line treatment, the proportion of patients receiving a BZD was greater before than after implementation (36% [10/28] and 26% [6/23], respectively). For first-line treatment, the mean lorazepam dose for patients weighing 40 kg or less was suboptimal (0.08 [standard deviation 0.03] mg/kg in both groups). Median time from hospital arrival to treatment was 7 minutes before and 6 minutes after implementation of the algorithm. For first-line treatment, the choice of ASM and the doses were compliant with the algorithm for 98% (43/44) and 53% (23/43) of patients, respectively. Conclusions: Implementation of the drug treatment algorithm brought limited changes at the study hospital. More specifically, choice of ASM and time between seizure onset and administration of ASM were similar before and after implementation. Weight-based doses of lorazepam remained suboptimal. Additional training should be given to clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.